Receive a copy of our current research models and services product guide.
Revolutionize Drug Discovery with Inotiv’s Comprehensive Neuroscience Program
Developing Antibody Drug Conjugate (ADC) therapeutics? Inotiv has mass spectrometry assays to quantify your ADC target protein in any sample type, including FFPE tissue, without antibodies. We have developed assays to 27 ADC targets for oncology and other therapeutic applications.
Reduce costs with our complimentary sample for evaluation in your lab.
Search by therapeutic area, research phase, and products and services at inotiv.com.
Inotiv delivers a broad array of nonclinical and analytical services from discovery through clinical development.
Inotiv provides the broadest range of research models and related services to pharmaceutical and biotech companies, government, academia, and other life science organizations.
April 25-30, 2025 Chicago, IL Booth #2509 The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research—from population science and preventio...
May 4-7, 2025 Boston, MA Booth #207 At NBC, leading scientists will gather to present and debate innovative solutions, gain insight into new emerging trends, and collaborative oppo...
May 7-9, 2025 Newark, DE The Genetic Toxicology Association (GTA) is a tax-exempt educational and scientific organization that was founded in 1975 and in...
April 23, 2025 WEST LAFAYETTE, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”...
February 05, 2025 Enhanced liquidity by $27.5 million through the issuance of ...
January 22, 2025 WEST LAFAYETTE, Ind., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”),
How Differences Between Experimental IBD Models Can Impact Your Drug Development Program
Due to the current FDA concern and guidance on reducing the risk of Nitrosamine impurities in human drugs, there has been an increased industry need for testing of these impurities using the Bacterial Reverse Mutation (Ames) test. As Nitrosamines are not readily detectable by standard Ames methodologies, specifically cited in the Ames testing guideline (OECD 471), the need for a robust protocol better suited for this class of compounds is warranted.
Copyright © 2025 Inotiv. All Rights Reserved.